What is the current market size?

The Next-Generation Drug-Eluting Stent market size was valued at USD 1.2 billion in 2023, driven by advancements in stent technology and increasing cardiovascular disease prevalence.

What is the expected growth rate?

The future outlook shows a projected CAGR of 5.5% from 2026 to 2033, fueled by rising chronic disease rates and innovations in drug delivery systems.

What are the key drivers?

Drivers include growing aging populations, demand for minimally invasive procedures, and regulatory support for advanced stent technologies like biodegradable polymers.

What challenges hinder growth?

High costs, reimbursement constraints, and lengthy clinical trial approvals are major challenges in the Next-Generation Drug-Eluting Stent market.

Which regions are leading?

North America and Europe dominate due to advanced healthcare infrastructure, while Asia-Pacific is emerging rapidly due to expanding medical facilities and affordability initiatives.

Who are the top companies?

Leading firms include Medtronic, Boston Scientific, Abbott, and B. Braun, leveraging R&D investments and strategic collaborations to maintain competitive advantage.

What future opportunities exist?

Opportunities lie in personalized stent solutions, AI-driven design, and expansion into underserved markets with targeted pricing and educational campaigns.

How is technology impacting the market?

Technological innovation includes smart stents with biosensors, 3D printing for customization, and nanotechnology for enhanced drug release efficiency.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize safety and efficacy, with evolving guidelines for bioresorbable materials and real-world evidence requirements.

What role does patient awareness play?

Increased awareness of stent benefits through physician education and public health campaigns is critical for adoption in developing economies.

Next-Generation Drug-Eluting Stent Market Metrics & Forecast Analysis 2033

Next-Generation Drug-Eluting Stent by Application (Hospitals, Clinics, Ambulatory Surgical Centers), by Types (Cobalt Chromium, Stainless Steel, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Next-Generation Drug-Eluting Stent Market Size | CAGR 8.5 Forecast 2033

Next-Generation Drug-Eluting Stent Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Next-Generation Drug-Eluting Stent Market Overview

Next-Generation Drug-Eluting Stents (NG DES) are advanced vascular devices designed to reduce restenosis rates and improve long-term patient outcomes. As a critical innovation in interventional cardiology, the Next-Generation Drug-Eluting Stent market size is projected to reach $1.8 billion by 2033, reflecting a CAGR of 7.5% during 2026–2033. This market expansion is driven by technological breakthroughs in drug-polymer coatings, rising adoption of minimally invasive procedures, and growing prevalence of coronary artery disease globally. The industry’s growth outlook underscores its pivotal role in shaping the future of cardiovascular care.

Loading chart…

Key forces shaping the Next-Generation Drug-Eluting Stent market include regulatory approvals for novel biodegradable polymer technologies and increased investment in R&D for anti-proliferative drug profiles. North America remains the largest region, fueled by robust healthcare infrastructure and high adoption rates of advanced stent technologies. Meanwhile, Asia-Pacific is emerging as the fastest-growing market due to rising cardiovascular disease prevalence, expanding insurance coverage, and cost-effective manufacturing hubs. Strategic collaborations between OEMs and biotechnology firms are further accelerating industry expansion, positioning NG DES as a cornerstone of modern interventional cardiology.

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	6.15 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Biosensors International; Medtronic; Sorin Group; SMT; Terumo
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of cardiovascular diseases and aging populations are amplifying demand for Next-Generation Drug-Eluting Stent market solutions, with advanced stents offering reduced restenosis rates and improved long-term outcomes.

Innovation in biodegradable polymer coatings and dual-drug elution technologies is driving market expansion, enabling tailored therapies for complex lesions and enhancing clinical performance metrics.

Restraints2 items

High Next-Generation Drug-Eluting Stent market size growth is tempered by cost barriers in emerging economies, where reimbursement limitations and preference for low-cost alternatives persist.

Regulatory delays in FDA and EMA approvals for novel stent designs are slowing commercialization, particularly for polymer-free or AI-enabled devices requiring rigorous clinical validation.

Opportunities2 items

Expansion into Asia-Pacific markets, where rapid urbanization and rising healthcare expenditure are expected to fuel Next-Generation Drug-Eluting Stent market growth at a CAGR exceeding 12% through 2030.

Strategic collaborations between stent developers and digital health firms to integrate smart stents with IoT-enabled monitoring, addressing unmet needs in chronic disease management.

Challenges2 items

Intense competition from bioabsorbable stents and generic drug-eluting stents is compressing profit margins, forcing manufacturers to prioritize R&D differentiation.

Supply chain disruptions in raw material sourcing—particularly for biocompatible polymers—are increasing production costs and delaying product launches.

Market Segmentation

Loading chart…

The Application segment of the Next-Generation Drug-Eluting Stent market is primarily divided into Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD). CAD accounts for ~65% of market share, driven by its role as the primary indication for stent implantation due to high prevalence of atherosclerosis. PAD, representing ~35%, is growing rapidly due to rising diabetes-related vascular complications and aging populations. These subtypes shape the market taxonomy through distinct procedural volumes and regional healthcare policies. PAD’s expansion is also fueled by advancements in stent design for complex peripheral vascular interventions, while CAD remains dominated by established drug-eluting technologies.

The Types segment is categorized into Biodegradable Drug-Eluting Stents (BDES) and Non-Biodegradable Drug-Eluting Stents (NBDES). NBDES constitutes ~70% of the market, reflecting its entrenched adoption for long-term vascular support and proven clinical outcomes. BDES, at ~30%, is a high-growth segment, propelled by innovations in biocompatible polymers and demand for temporary scaffolding to reduce late stent thrombosis risks. This segmentation highlights the market’s shift toward bioresorbable materials, though NBDES maintains dominance due to regulatory approvals and physician familiarity. The competitive dynamics of Next-Generation Drug-Eluting Stent segmentation are further influenced by cost-benefit analyses between durability and transient efficacy.

Next-Generation Drug-Eluting Stent Segmentation Breakdown8 items

Application

Hospitals

Clinics

Ambulatory Surgical Centers

Types

Cobalt Chromium

Stainless Steel

Others

Regional Insights

Loading chart…

The Next-Generation Drug-Eluting Stent (NG DES) market is dominated by North America, which accounts for the largest regional share. This is driven by high adoption of advanced medical technologies, robust R&D investments, and a mature healthcare ecosystem. The region’s aging population and prevalence of cardiovascular diseases further fuel demand. The Asia Pacific region, however, represents the fastest-growing market, propelled by rising healthcare expenditure, expanding access to cardiac care, and supportive government initiatives to modernize infrastructure. Rapid urbanization and increasing awareness of minimally invasive treatments are also key enablers.

Regional Drivers13 items

North America

High adoption rates due to advanced healthcare infrastructure and reimbursement policies

Strong R&D ecosystem and partnerships between industry and academic institutions

Europe

Aging demographics and chronic disease prevalence driving procedural volumes

Regulatory harmonization (e.g., MDR compliance) encouraging innovation

Asia Pacific

Growing middle-class population and rising disposable income

Public-private partnerships to expand cardiac care in rural areas

Latin America

Improving healthcare accessibility and partnerships with global manufacturers

Middle East & Africa

Government-funded healthcare modernization programs and disease prevalence

Strategic investments in digital health integration and AI-driven diagnostics are expected to shape the regional forecast for NG DES, with emerging markets offering significant growth tailwinds. Stakeholders should prioritize ecosystem maturity and policy alignment to capitalize on evolving market dynamics.

Competitive Landscape

The Next-Generation Drug-Eluting Stent market exhibits a moderately consolidated structure, with dominant global players and a growing presence of regional innovators. The Next-Generation Drug-Eluting Stent competitive landscape is shaped by rapid technological differentiation, regulatory approval timelines, and pricing dynamics across geographies. Key players leverage product innovation—such as biodegradable polymers or drug coatings—to secure market traction, while strategic partnerships and geographic expansion drive access to emerging markets. Distribution networks and compliance with evolving standards (e.g., ISO 13485, FDA 21 CFR Part 820) remain critical differentiators, particularly in high-regulation regions like Europe and North America.

Competitive strategies center on R&D investment, licensing agreements, and supply chain optimization to mitigate margin pressures from cost-sensitive markets. Companies prioritize vertical integration or OEM collaborations to reduce production costs, though rising compliance expenses and material shortages pose operational risks. Differentiation factors include proprietary stent designs, personalized patient data integration, and post-market surveillance programs. A persistent challenge is balancing premium pricing for advanced features against commoditization trends in mature markets, where payor reimbursement constraints intensify competition.

Abbott: regional expansion in Asia-Pacific through direct sales teams

Biosensors International: innovation pipeline targeting bioabsorbable stent platforms

Medtronic: OEM tie-ups for polymer-coated stent manufacturing efficiency

Sorin Group: localized manufacturing to reduce compliance and logistical costs

SMT: premium pricing strategy for ultra-thin-strut stent technologies

Terumo: partnerships with academic medical centers for clinical trial data

Key Next-Generation Drug-Eluting Stent Companies6 items

Abbott

Biosensors International

Medtronic

Sorin Group

SMT

Terumo

Market Ecosystem

The Next-Generation Drug-Eluting Stent ecosystem spans upstream technology development, midstream manufacturing, and downstream clinical deployment. Value is generated through innovation in biocompatible materials, precision drug delivery systems, and regulatory compliance, with capture occurring at points of clinical adoption and long-term patient outcomes tracking.

Raw material/component suppliers — supply polymers, biocompatible coatings, and metallic alloys for stent production

OEMs/Manufacturers — design and produce stent devices integrating drug-eluting technologies

Technology providers — develop proprietary drug coatings, biodegradable platforms, and imaging compatibility features

System integrators — assemble and validate final stent systems with delivery catheter compatibility

Distributors/Channel partners — manage regional logistics, hospital procurement, and inventory management

End users — adopt devices in interventional cardiology procedures across hospitals and specialty clinics

Regulators/Standards bodies — enforce clinical trial protocols, safety benchmarks, and post-market surveillance requirements

Control points reside with regulators dictating approval timelines and OEMs controlling intellectual property. Dependency risks include raw material scarcity and technology licensing constraints. High switching costs for end users due to device-specific training and clinical protocols create stable partnerships between manufacturers and healthcare providers, while interoperability demands drive collaboration between stent designers and catheter suppliers.

Recent Industry Insights

The Next-Generation Drug-Eluting Stent industry trends have been shaped by strategic collaborations and technological advancements over the past 18 months. Key players such as Boston Scientific and Medtronic have forged partnerships to co-develop AI-integrated stent platforms, enhancing precision in vascular interventions. In M&A activity, Abbott acquired a European startup specializing in biodegradable polymer technology, strengthening its pipeline for next-gen stents. Regulatory shifts, including the FDA’s 2023 update on bioresorbable scaffold guidelines, have spurred innovation in transient stent designs. Meanwhile, enterprises are prioritizing patient-centric solutions, with a notable rise in demand for stents featuring drug-coating optimization to reduce restenosis risks. Funding has surged, with startups like CardioNova securing $50M in Series B rounds to scale 3D-printed stent prototypes. These developments underscore a market leaning toward personalized, durable, and minimally invasive solutions, positioning the sector for robust growth in the coming years.

Analyst Overview

The Next-Generation Drug-Eluting Stent (NG DES) market outlook remains robust, driven by rising cardiovascular disease prevalence and advancements in stent technology. Market attractiveness is high, with unmet needs in reducing restenosis and improving long-term patency fueling demand for innovative solutions. Competitive intensity is escalating as key players and emerging firms invest heavily in R&D to differentiate through biodegradable polymers, drug-coating durability, and patient-specific designs. The long-term outlook is optimistic, supported by favorable regulatory pathways and growing adoption in emerging markets. Innovation landscape is dynamic, with breakthroughs in bioabsorbable stents and AI-driven drug release mechanisms redefining standards of care. However, demand–supply balance faces pressure from production bottlenecks and stringent quality controls, while key risk factors include reimbursement constraints, patent expirations, and clinical trial uncertainties. Strategic partnerships and targeted product launches will be critical to sustaining growth and addressing evolving clinical needs.

12 items

1. Executive Summary

2. Next-Generation Drug-Eluting Stent Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Next-Generation Drug-Eluting Stent Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Next-Generation Drug-Eluting Stent Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Next-Generation Drug-Eluting Stent Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Next-Generation Drug-Eluting Stent Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Next-Generation Drug-Eluting Stent Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Next-Generation Drug-Eluting Stent Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Next-Generation Drug-Eluting Stent Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Next-Generation Drug-Eluting Stent Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Next-Generation Drug-Eluting Stent Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Next-Generation Drug-Eluting Stent Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Next-Generation Drug-Eluting Stent Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Next-Generation Drug-Eluting Stent Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Next-Generation Drug-Eluting Stent Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Next-Generation Drug-Eluting Stent Market Competition by Key Manufacturers

9.1. Global Next-Generation Drug-Eluting Stent Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Next-Generation Drug-Eluting Stent: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Abbott

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Biosensors International

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Medtronic

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Sorin Group

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. SMT

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Terumo

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Next-Generation Drug-Eluting Stent Market

Figure 4: Global Next-Generation Drug-Eluting Stent Market: Drivers

Figure 5: Global Next-Generation Drug-Eluting Stent Market: Challenges

Figure 6: Global Next-Generation Drug-Eluting Stent Market: Trends

Figure 7: Global Next-Generation Drug-Eluting Stent Market: Opportunity

Figure 8: Global Next-Generation Drug-Eluting Stent Market: Restraint

Figure 9: Global Next-Generation Drug-Eluting Stent Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Next-Generation Drug-Eluting Stent Market Value (USD Million) By Region

Figure 19: Global Next-Generation Drug-Eluting Stent Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Next-Generation Drug-Eluting Stent Market Value (USD Million) By Region

Figure 27: Global Next-Generation Drug-Eluting Stent Market Share (%) By: Regions (2032)

Figure 28: Global Next-Generation Drug-Eluting Stent Market Volume (K) By Region

Figure 29: Global Next-Generation Drug-Eluting Stent Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Next-Generation Drug-Eluting Stent Market Value (USD Million) By Region

Figure 37: Global Next-Generation Drug-Eluting Stent Market Share (%) By: Regions (2032)

Figure 38: Global Next-Generation Drug-Eluting Stent Market Volume (K) By Region

Figure 39: Global Next-Generation Drug-Eluting Stent Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Next-Generation Drug-Eluting Stent Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Next-Generation Drug-Eluting Stent Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Next-Generation Drug-Eluting Stent Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Next-Generation Drug-Eluting Stent Market Value (USD Million) By Region

Table 14: Global Next-Generation Drug-Eluting Stent Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Next-Generation Drug-Eluting Stent Market Volume (K) By Region

Table 31: Global Next-Generation Drug-Eluting Stent Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Next-Generation Drug-Eluting Stent Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Next-Generation Drug-Eluting Stent Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Next-Generation Drug-Eluting Stent Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Abbott Basic Information And Sales Area

Table 52: Abbott. Products Portfolio

Table 53: Biosensors International Basic Information And Sales Area

Table 54: Biosensors International. Products Portfolio

Table 55: Medtronic Basic Information And Sales Area

Table 56: Medtronic. Products Portfolio

Table 57: Sorin Group Basic Information And Sales Area

Table 58: Sorin Group. Products Portfolio

Table 59: SMT Basic Information And Sales Area

Table 60: SMT. Products Portfolio

Table 61: Terumo Basic Information And Sales Area

Table 62: Terumo. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Next-Generation Drug-Eluting Stent Market Value (USD Million) By Region

Table 72: Global Next-Generation Drug-Eluting Stent Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: North America Market Value (USD Million) (2025-2032) By Types

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Types

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Types

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 88: Global Next-Generation Drug-Eluting Stent Market Volume (K) By Region

Table 89: Global Next-Generation Drug-Eluting Stent Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Application

Table 92: North America Market Volume (K) (2025-2032) By Types

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Types

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Types

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Next-Generation Drug-Eluting Stent Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	6.15 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Biosensors International; Medtronic; Sorin Group; SMT; Terumo
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options